ImmunoCellular Therapeutics (NASDAQ:IMUC) posted its quarterly earnings results on Monday. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.06) by $0.02, Stock Ratings News reports.
A number of analysts have recently weighed in on IMUC shares. Analysts at Roth Capital upgraded shares of ImmunoCellular Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $3.00 price target on the stock, up previously from $2.00. Analysts at Maxim Group cut their price target on shares of ImmunoCellular Therapeutics from $12.00 to $4.00 in a research note on Monday, June 2nd. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $3.31.
Shares of ImmunoCellular Therapeutics (NASDAQ:IMUC) opened at 0.89 on Tuesday. ImmunoCellular Therapeutics has a 52 week low of $0.65 and a 52 week high of $4.00. The stock has a 50-day moving average of $1.02 and a 200-day moving average of $1.18. The company’s market cap is $51.6 million.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.